Ocular Therapeutix Inc (OCUL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.37B
Last updated: Nov 17, 2026 at 11:06 AM ET
Ocular Therapeutix Inc (OCUL) Earnings: Report Dates and Results
Ocular Therapeutix (OCUL) is expected to report earnings on Feb 3, 2027. In the quarter ended Sep 30, 2026, Ocular Therapeutix reported EPS of -$0.42, below the -$0.36 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
OCUL has an expected report date of Feb 3, 2027.
OCUL Earnings Call
The latest OCUL earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, OCUL beat 11, missed 28 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $12.87M, down 11.5% from $14.54M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.42 | -$0.36 | -$0.37 - -$0.30 | -16.67% | Miss | N/A | 6 | 4 up, 0 down | Nov 9, 2026 | $12.87M |
| Jun 30, 2026 | -$0.35 | -$0.40 | -$0.42 - -$0.31 | +12.50% | Beat | N/A | 4 | 0 up, 1 down | Aug 3, 2026 | $13.47M |
| Mar 31, 2026 | -$0.40 | -$0.31 | -$0.36 - -$0.26 | -29.03% | Miss | N/A | 4 | 1 up, 0 down | May 5, 2026 | $10.79M |
| Dec 31, 2025 | -$0.29 | -$0.34 | -$0.36 - -$0.31 | +14.71% | Beat | N/A | 3 | 1 up, 1 down | Feb 5, 2026 | $13.25M |
| Sep 30, 2025 | -$0.38 | -$0.35 | -$0.39 - -$0.31 | -8.57% | Miss | N/A | 3 | 2 up, 0 down | Nov 4, 2025 | $14.54M |
| Jun 30, 2025 | -$0.39 | -$0.35 | -$0.38 - -$0.30 | -11.43% | Miss | N/A | 4 | 0 up, 3 down | Aug 5, 2025 | $13.46M |
| Mar 31, 2025 | -$0.37 | -$0.28 | -$0.30 - -$0.25 | -32.14% | Miss | N/A | 3 | 0 up, 3 down | May 5, 2025 | $10.70M |
| Dec 31, 2024 | -$0.29 | -$0.22 | -$0.26 - -$0.14 | -31.82% | Miss | N/A | 5 | 0 up, 3 down | Mar 3, 2025 | $17.08M |
| Sep 30, 2024 | -$0.22 | -$0.21 | -$0.25 - -$0.16 | -4.76% | Miss | N/A | 3 | 1 up, 0 down | Nov 14, 2024 | $15.43M |
| Jun 30, 2024 | -$0.26 | -$0.21 | -$0.25 - -$0.14 | -23.81% | Miss | N/A | 7 | 0 up, 0 down | Aug 7, 2024 | $16.44M |
| Mar 31, 2024 | -$0.24 | -$0.18 | -$0.31 - -$0.14 | -33.33% | Miss | N/A | 7 | 0 up, 0 down | May 7, 2024 | $14.77M |
| Dec 31, 2023 | -$0.35 | -$0.30 | -$0.54 - -$0.19 | -16.67% | Miss | N/A | 8 | 1 up, 0 down | Mar 11, 2024 | $14.80M |
| Sep 30, 2023 | -$0.19 | -$0.25 | -$0.34 - -$0.21 | +24.00% | Beat | N/A | 7 | 0 up, 0 down | Nov 7, 2023 | $15.08M |
| Jun 30, 2023 | -$0.26 | -$0.29 | -$0.41 - -$0.25 | +10.34% | Beat | N/A | 7 | 0 up, 0 down | Aug 7, 2023 | $15.19M |
| Mar 31, 2023 | -$0.31 | -$0.24 | -$0.28 - -$0.24 | -29.17% | Miss | N/A | 6 | 0 up, 0 down | May 8, 2023 | $13.37M |
| Dec 31, 2022 | -$0.24 | -$0.25 | -$0.28 - -$0.20 | +4.00% | Beat | N/A | 6 | 0 up, 0 down | Mar 6, 2023 | $14.08M |
| Sep 30, 2022 | -$0.30 | -$0.21 | -$0.28 - -$0.15 | -42.86% | Miss | N/A | 5 | 0 up, 0 down | Nov 7, 2022 | $11.96M |
| Jun 30, 2022 | -$0.21 | -$0.18 | N/A | -16.67% | Miss | N/A | N/A | 0 up, 0 down | Aug 8, 2022 | $12.27M |
| Mar 31, 2022 | -$0.25 | -$0.22 | N/A | -13.64% | Miss | N/A | 2 | 0 up, 0 down | May 9, 2022 | $13.19M |
| Dec 31, 2021 | -$0.05 | -$0.23 | -$0.26 - -$0.21 | +78.26% | Beat | N/A | 4 | N/A | Feb 28, 2022 | $12.31M |
| Sep 30, 2021 | -$0.28 | -$0.26 | -$0.30 - -$0.20 | -7.69% | Miss | N/A | 4 | 1 up, 0 down | Nov 8, 2021 | $12.15M |
| Jun 30, 2021 | -$0.29 | -$0.21 | -$0.24 - -$0.16 | -38.10% | Miss | N/A | 6 | N/A | Aug 9, 2021 | $11.72M |
| Mar 31, 2021 | -$0.29 | -$0.21 | -$0.25 - -$0.17 | -38.10% | Miss | N/A | 6 | N/A | May 5, 2021 | $7.34M |
| Dec 31, 2020 | -$1.21 | -$0.17 | -$0.23 - -$0.07 | -611.76% | Miss | N/A | 6 | N/A | Mar 11, 2021 | $7.35M |
| Sep 30, 2020 | -$0.19 | -$0.25 | -$0.28 - -$0.20 | +24.00% | Beat | N/A | 4 | N/A | Nov 5, 2020 | $5.88M |
| Jun 30, 2020 | -$0.64 | -$0.32 | -$0.35 - -$0.29 | -100.00% | Miss | N/A | 5 | N/A | Aug 7, 2020 | $1.57M |
| Mar 31, 2020 | -$0.41 | -$0.49 | N/A | +16.33% | Beat | N/A | 3 | N/A | May 8, 2020 | $2.61M |
| Dec 31, 2019 | -$0.53 | -$0.45 | -$0.46 - -$0.43 | -17.78% | Miss | N/A | 3 | N/A | Mar 12, 2020 | $2.26M |
| Sep 30, 2019 | -$0.45 | -$0.46 | -$0.52 - -$0.38 | +2.17% | Beat | N/A | 4 | N/A | Nov 12, 2019 | $829000 |
| Jun 30, 2019 | -$0.57 | -$0.48 | -$0.49 - -$0.46 | -18.75% | Miss | N/A | 4 | N/A | Aug 7, 2019 | $650000 |
| Mar 31, 2019 | -$0.48 | -$0.42 | -$0.45 - -$0.38 | -14.29% | Miss | N/A | 5 | N/A | May 10, 2019 | $492000 |
| Dec 31, 2018 | -$0.42 | -$0.38 | -$0.40 - -$0.37 | -10.53% | Miss | N/A | 6 | N/A | Mar 7, 2019 | $504000 |
| Sep 30, 2018 | -$0.38 | -$0.37 | -$0.41 - -$0.34 | -2.70% | Miss | N/A | 5 | N/A | Nov 7, 2018 | $498000 |
| Jun 30, 2018 | -$0.37 | -$0.37 | -$0.39 - -$0.36 | 0.00% | In line | N/A | 4 | N/A | Aug 7, 2018 | $648000 |
| Mar 31, 2018 | -$0.40 | -$0.41 | -$0.44 - -$0.28 | +2.44% | Beat | N/A | 5 | N/A | May 8, 2018 | $340000 |
| Dec 31, 2017 | -$0.44 | -$0.52 | -$0.61 - -$0.47 | +15.38% | Beat | N/A | 5 | N/A | Mar 8, 2018 | $925000 |
| Sep 30, 2017 | -$0.54 | -$0.53 | -$0.60 - -$0.47 | -1.89% | Miss | N/A | 5 | N/A | Nov 7, 2017 | $523000 |
| Jun 30, 2017 | -$0.64 | -$0.57 | -$0.61 - -$0.52 | -12.28% | Miss | N/A | 4 | N/A | Aug 8, 2017 | N/A |
| Mar 31, 2017 | -$0.58 | -$0.48 | N/A | -20.83% | Miss | N/A | N/A | N/A | May 5, 2017 | $475000 |
| Dec 31, 2016 | -$0.52 | -$0.45 | N/A | -15.56% | Miss | N/A | N/A | N/A | Mar 10, 2017 | $511000 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.43, after -$1.01 the year before. It was -$1.80 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.43 | N/A |
| Dec 31, 2024 | -$1.01 | N/A |
| Dec 31, 2023 | -$1.11 | N/A |
| Dec 31, 2022 | -$1.00 | N/A |
| Dec 31, 2021 | -$0.91 | N/A |
| Dec 31, 2020 | -$2.45 | N/A |
| Dec 31, 2019 | -$2.03 | N/A |
| Dec 31, 2018 | -$1.57 | N/A |
| Dec 31, 2017 | -$2.20 | N/A |
| Dec 31, 2016 | -$1.80 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,700 words across 10 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,695 | 10 | |
| 2026Q1 | Mar 31, 2026 | 5,293 | 11 | |
| 2025Q3 | Sep 30, 2025 | 5,910 | 10 | |
| 2025Q2 | Jun 30, 2025 | 7,912 | 14 | |
| 2024Q4 | Dec 31, 2024 | 6,602 | 11 | |
| 2024Q3 | Sep 30, 2024 | 4,332 | 12 | |
| 2024Q2 | Jun 30, 2024 | 4,292 | 11 |
2026Q3 Earnings Call
Opening remarks
William Slattery Vice President of Investor Relations Good morning, everyone, and thank you for joining us today. Earlier this morning, we issued a press release and filed our quarterly report on Form 10-Q, outlining our financial results and business updates for the third quarter of 2026. We will begin today's call with prepared remarks summarizing recent business highlights from Dr. Pravin Dugel, Ocular's Executive Chairman, President and CEO; Dr. Nadia Waheed, Ocular's Chief Medical Officer; and David Robinson, Ocular's Global Chief Commercial Officer. Donald Notman, Ocular's Chief Operating Officer, will join for the question-and-answer session. We refer everyone to this morning's press release and our Form 10-Q for a comprehensive update of third quarter 2026 financial and business results. During today's call, certain statements we will be making constitute forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially as a result of a variety of factors, including risks and uncertainties identified in the Risk Factors section of our annual report on Form 10-K and our other SEC filings. On today's call, we will discuss our investigational product candidate, AXPAXLI, also known as OTX-TKI, which is in development for wet age-related macular degeneration and non-proliferative diabetic retinopathy. As a reminder, the safety and efficacy of AXPAXLI have not been established by the FDA or any other regulatory authority, and AXPAXLI has not been approved for marketing. With that, I'd like to hand the call over to Dr. Pravin Dugel to review our recent updates. Pravin?
Pravin Dugel Executive Chairman, President and CEO Thanks, Bill, and good morning, everyone. 2026 has been an extraordinary and truly transformational year for Ocular Therapeutix. We have achieved landmark Phase III superiority results in SOL-1, established a clear regulatory path forward toward our first potential approval for AXPAXLI in wet AMD, and continue to generate compelling clinical evidence showing AXPAXLI's durability and disease control. As we approach the end of the year, I believe we are in the strongest position in our company's 20-year history, with an extraordinary opportunity to fundamentally transform the treatment paradigm for retinal diseases. Today, while several bolus treatment agents are either approved or in development, AXPAXLI stands alone as the only intravitreal sustained-release maintenance agent with positive Phase III data in wet AMD. With the competitive landscape evolving significantly in recent months, we believe our opportunity has never been greater. I want to begin by addressing recent competitive developments because they reinforce the importance of the fundamental principles that have guided our AXPAXLI development strategy from the onset. These include the importance of TKI potency, drug delivery vehicle, and thoughtful clinical trial design, including rigorous patient selection. In drug development, molecular potency matters. The drug delivery vehicle matters.
Frequently Asked Questions About OCUL
When is Ocular Therapeutix's next earnings date?
Ocular Therapeutix's next earnings report is expected for Feb 3, 2027.
Did OCUL beat earnings estimates last quarter?
No. Ocular Therapeutix reported EPS of -$0.42 for the quarter ended Sep 30, 2026, below the -$0.36 estimate by 16.67%.
What EPS do analysts expect from OCUL next quarter?
The consensus EPS estimate for Ocular Therapeutix for the quarter ending Dec 31, 2026 is -$0.42 from 15 analysts, with estimates from -$0.44 to -$0.39.
How often does OCUL beat earnings estimates?
Ocular Therapeutix beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -12.81%.
OCUL pages: Overview, Earnings, Forecast, Financials, Competitors